Literature DB >> 19806445

Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Rebecca E Rosenberg1, David S Mandell, Janet E Farmer, J Kiely Law, Alison R Marvin, Paul A Law.   

Abstract

Patterns of current psychotropic medication use among 5,181 children with autism spectrum disorders (ASD) enrolled in a Web-based registry were examined. Overall, 35% used at least one psychotropic medication, most commonly stimulants, neuroleptics, and/or antidepressants. Those who were uninsured or exclusively privately insured were less likely to use >or=3 medications than were those insured by Medicaid. Psychiatrists and neurologists prescribed the majority of psychotropic medications. In multivariate analysis, older age, presence of intellectual disability or psychiatric comorbidity, and residing in a poorer county or in the South or Midwest regions of the United States increased the odds of psychotropic medication use. Factors external to clinical presentation likely affect odds of psychotropic medication use among children with ASD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19806445     DOI: 10.1007/s10803-009-0878-1

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  28 in total

1.  Datapoints: use of multiple psychotropic drugs by Medicaid-insured and privately insured children.

Authors:  Andrés Martin; Tierney Sherwin; Dorothy Stubbe; Thomas Van Hoof; Lawrence Scahill; Douglas Leslie
Journal:  Psychiatr Serv       Date:  2002-12       Impact factor: 3.084

2.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

Authors:  Mark Olfson; Carlos Blanco; Linxu Liu; Carmen Moreno; Gonzalo Laje
Journal:  Arch Gen Psychiatry       Date:  2006-06

3.  Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.

Authors:  Julie Magno Zito; Daniel J Safer; Ilene H Zuckerman; James F Gardner; Karen Soeken
Journal:  Psychiatr Serv       Date:  2005-02       Impact factor: 3.084

4.  Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation.

Authors:  Annelies de Bildt; Erik J Mulder; Tom Scheers; Ruud B Minderaa; Hilde Tobi
Journal:  Pediatrics       Date:  2006-12       Impact factor: 7.124

5.  Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society.

Authors:  P A Filipek; P J Accardo; S Ashwal; G T Baranek; E H Cook; G Dawson; B Gordon; J S Gravel; C P Johnson; R J Kallen; S E Levy; N J Minshew; S Ozonoff; B M Prizant; I Rapin; S J Rogers; W L Stone; S W Teplin; R F Tuchman; F R Volkmar
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

6.  Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.

Authors:  A Martin; L Scahill; A Klin; F R Volkmar
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-07       Impact factor: 8.829

7.  Medication management of stimulants in pediatric practice settings: a national perspective.

Authors:  K Hoagwood; P S Jensen; M Feil; B Vitiello; V S Bhatara
Journal:  J Dev Behav Pediatr       Date:  2000-10       Impact factor: 2.225

8.  Internet survey of treatments used by parents of children with autism.

Authors:  Vanessa A Green; Keenan A Pituch; Jonathan Itchon; Aram Choi; Mark O'Reilly; Jeff Sigafoos
Journal:  Res Dev Disabil       Date:  2006 Jan-Feb

9.  Medication patterns in patients with autism: temporal, regional, and demographic influences.

Authors:  Michael G Aman; Kristen S L Lam; Mary E Van Bourgondien
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-02       Impact factor: 2.576

Review 10.  Management of children with autism spectrum disorders.

Authors:  Scott M Myers; Chris Plauché Johnson
Journal:  Pediatrics       Date:  2007-10-29       Impact factor: 7.124

View more
  45 in total

1.  Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder.

Authors:  Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-13       Impact factor: 2.576

2.  Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.

Authors:  Lawrence Scahill; Christopher J McDougle; Michael G Aman; Cynthia Johnson; Benjamin Handen; Karen Bearss; James Dziura; Eric Butter; Naomi G Swiezy; L Eugene Arnold; Kimberly A Stigler; Denis D Sukhodolsky; Luc Lecavalier; Stacie L Pozdol; Roumen Nikolov; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; Arlene E Kohn; Kathleen Koenig; Stacie Grinnon; James A Mulick; Sunkyung Yu; Benedetto Vitiello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-12-23       Impact factor: 8.829

3.  Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.

Authors:  Melisa Carrasco; Fred R Volkmar; Michael H Bloch
Journal:  Pediatrics       Date:  2012-04-23       Impact factor: 7.124

4.  ASD, a psychiatric disorder, or both? Psychiatric diagnoses in adolescents with high-functioning ASD.

Authors:  Carla A Mazefsky; Donald P Oswald; Taylor N Day; Shaun M Eack; Nancy J Minshew; Janet E Lainhart
Journal:  J Clin Child Adolesc Psychol       Date:  2012-05-29

5.  Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Authors:  Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook
Journal:  Pharmacogenet Genomics       Date:  2015-11       Impact factor: 2.089

Review 6.  Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.

Authors:  Evdokia Anagnostou; Robin Hansen
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

7.  Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.

Authors:  Marco Lamberti; Rosamaria Siracusano; Domenico Italiano; Norma Alosi; Francesca Cucinotta; Gabriella Di Rosa; Eva Germanò; Edoardo Spina; Antonella Gagliano
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

8.  Managing anxiety and depressive symptoms in adults with autism-spectrum disorders.

Authors:  Kerry Boyd; Marc Woodbury-Smith; Peter Szatmari
Journal:  J Psychiatry Neurosci       Date:  2011-07       Impact factor: 6.186

9.  Aberrant Behaviors and Co-occurring Conditions as Predictors of Psychotropic Polypharmacy among Children with Autism Spectrum Disorders.

Authors:  Sarah L Logan; Laura Carpenter; R Scott Leslie; Elizabeth Garrett-Mayer; Kelly J Hunt; Jane Charles; Joyce S Nicholas
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

10.  Is Medication Information for Children with Autism Spectrum Disorder Monitored and Coordinated Across Professionals? Findings from a Teacher Survey.

Authors:  Lynn K Koegel; Anna M Krasno; Howard Taras; Robert L Koegel; William Frea
Journal:  School Ment Health       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.